TY - JOUR
T1 - The cardiovascular risk factor, soluble CD40 ligand (CD154), but not Soluble CD40 is lowered by ultra-endurance exercise in athletes
AU - Geertsema, L.
AU - Lucas, S.J.E.
AU - Cotter, J.D.
AU - Hock, B.
AU - McKenzie, J.
AU - Fernyhough, L.J.
PY - 2011/1/1
Y1 - 2011/1/1
N2 - Background: Soluble CD40 ligand (sCD40L) is a powerful marker of cardiovascular risk. Exercise is known to decrease cardiovascular risk, but the impact of ultra-endurance exercise on sCD40L responses is unknown. Objective: To examine the relationship between ultraendurance exercise in trained athletes and levels of sCD40L and its natural ligand sCD40. Design: Control-trial, crossover design, exercise intervention study of sCD40L and sCD40 levels. Setting: Outdoor exercise and laboratory testing, single centre study, School of Physical Education, University of Otago, New Zealand. Participants: Nine trained ultra-endurance athletes. Interventions: Athletes exercised (cycled and jogged) for 17 of 24 h. Venous blood was sampled at baseline and serially throughout exercise and 24 and 48 h after exercise. The athletes completed a 24 h control trial on a separate occasion, in randomised order. Main outcome measurements: Mean levels of sCD40L and sCD40 during exercise and rest with 95% CIs. Results: sCD40L levels dropped steadily from baseline (median 4128 pg/ml) to a measured nadir at 24 h following exercise (median 1409 pg/ml) (p=0.01). The levels had started to rise again by 48 h after exercise. When measured as a group, sCD40L levels remained constant during a control rest period. sCD40 levels remained constant on both exercise and control days. Conclusion: Ultra-endurance exercise lowers the levels of the cardiovascular risk marker sCD40L in athletes. These results raise the possibility that exercise-induced changes in sCD40L may provide one of the mechanisms by which exercise lowers cardiovascular risk.
AB - Background: Soluble CD40 ligand (sCD40L) is a powerful marker of cardiovascular risk. Exercise is known to decrease cardiovascular risk, but the impact of ultra-endurance exercise on sCD40L responses is unknown. Objective: To examine the relationship between ultraendurance exercise in trained athletes and levels of sCD40L and its natural ligand sCD40. Design: Control-trial, crossover design, exercise intervention study of sCD40L and sCD40 levels. Setting: Outdoor exercise and laboratory testing, single centre study, School of Physical Education, University of Otago, New Zealand. Participants: Nine trained ultra-endurance athletes. Interventions: Athletes exercised (cycled and jogged) for 17 of 24 h. Venous blood was sampled at baseline and serially throughout exercise and 24 and 48 h after exercise. The athletes completed a 24 h control trial on a separate occasion, in randomised order. Main outcome measurements: Mean levels of sCD40L and sCD40 during exercise and rest with 95% CIs. Results: sCD40L levels dropped steadily from baseline (median 4128 pg/ml) to a measured nadir at 24 h following exercise (median 1409 pg/ml) (p=0.01). The levels had started to rise again by 48 h after exercise. When measured as a group, sCD40L levels remained constant during a control rest period. sCD40 levels remained constant on both exercise and control days. Conclusion: Ultra-endurance exercise lowers the levels of the cardiovascular risk marker sCD40L in athletes. These results raise the possibility that exercise-induced changes in sCD40L may provide one of the mechanisms by which exercise lowers cardiovascular risk.
UR - http://www.scopus.com/inward/record.url?partnerID=yv4JPVwI&eid=2-s2.0-78650863251&md5=1f77b5facbd4ba4a3cd896d406f3fca0
U2 - 10.1136/bjsm.2008.051896
DO - 10.1136/bjsm.2008.051896
M3 - Article
AN - SCOPUS:78650863251
SN - 0306-3674
VL - 45
SP - 42
EP - 45
JO - British Journal of Sports Medicine
JF - British Journal of Sports Medicine
IS - 1
ER -